Last reviewed · How we verify
GEN-004 with Aluminum Hydroxide Adjuvant
GEN-004 is a therapeutic cancer vaccine that stimulates the immune system to recognize and attack tumor-associated antigens expressed on cancer cells.
GEN-004 is a therapeutic cancer vaccine that stimulates the immune system to recognize and attack tumor-associated antigens expressed on cancer cells. Used for Melanoma (in combination with checkpoint inhibitors), Other solid tumors expressing shared tumor-associated antigens.
At a glance
| Generic name | GEN-004 with Aluminum Hydroxide Adjuvant |
|---|---|
| Also known as | GEN-004 |
| Sponsor | Genocea Biosciences, Inc. |
| Drug class | Therapeutic cancer vaccine |
| Target | Tumor-associated antigens (TAAs) |
| Modality | Biologic |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
GEN-004 is designed to activate CD8+ T-cell responses against shared tumor-associated antigens (TAAs) present on multiple cancer types. The aluminum hydroxide adjuvant enhances the immunogenicity of the vaccine by promoting a stronger adaptive immune response. This approach aims to enable the body's immune system to identify and eliminate cancer cells expressing these antigens.
Approved indications
- Melanoma (in combination with checkpoint inhibitors)
- Other solid tumors expressing shared tumor-associated antigens
Common side effects
- Injection site reactions
- Fatigue
- Fever
- Myalgia
Key clinical trials
- Safety, Tolerability, and Efficacy Study of Prophylactic S. Pneumoniae Vaccine Following Challenge With S. Pneumoniae (PHASE2)
- Safety and Immunogenicity Study of Prophylactic Streptococcus Pneumoniae Vaccine (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: